Victoza was approved by FDA in January 2010. It is an injectable form of GLP-1 analog. It improves diabetes via several mechanisms; insulin sensitivity, appetite suppression, reduced gastrointestinal motility, lower glucagon and higher insulin release in response to food.
GT
Also see: